FY26 Results: Revenue Jumps 56%, But Profitability Declines
Accretion Pharmaceuticals Limited · ACCPL · NSE ·
**Strong Revenue Growth:** Total revenue grew by 56.3% YoY to ₹89.7 Cr in FY26, driven by strong performance in the Capsules (+87.8%) and Oral Liquids (+81.7%) segments. **Profitability Squeezed:** Despite strong sales, key profitability metrics declined. EBITDA margin fell to 16…